DSpace Repository

Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging

Show simple item record

dc.contributor Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades
dc.contributor.author Andreu-Crespo, A.
dc.contributor.author Llibre, Josep M.
dc.contributor.author Cardona-Peitx, G.
dc.contributor.author Sala-Piñol, F.
dc.contributor.author Clotet, Bonaventura
dc.contributor.author Bonafont-Pujol, X.
dc.date.accessioned 2015-10-05T09:49:04Z
dc.date.available 2015-10-05T09:49:04Z
dc.date.created 2015
dc.date.issued 2015
dc.identifier.citation Andreu-Crespo, À., Llibre, J. M., Cardona-Peitx, G., Sala-Piñol, F., Clotet, B., & Bonafont-Pujol, X. (2015). Hidden costs of antiretroviral treatment: The public health efficiency of drug packaging. Drug Design, Development and Therapy, 9, 4287-4290. ca_ES
dc.identifier.issn 1177-8881
dc.identifier.uri http://hdl.handle.net/10854/4271
dc.description.abstract While the overall percentage of unused antiretroviral medicines returned to the hospital pharmacy is low, their cost is quite high. Adverse events, treatment failure, pharmacokinetic interactions, pregnancy, or treatment simplification are common reasons for unplanned treatment changes. Socially inefficient antiretroviral packages prevent the reuse of drugs returned to the hospital pharmacy. We defined antiretroviral package categories based on the excellence of drug packaging and analyzed the number of pills and costs of drugs returned during a period of 1 year in a hospital-based HIV unit attending to 2,413 treated individuals. A total of 6,090 pills (34% of all returned antiretrovirals) - with a cost of 47,139.91 € - would be totally lost, mainly due to being packed up in the lowest efficiency packages. Newer treatments are packaged in low-excellence categories of packages, thus favoring the maintenance of these hidden costs in the near future. Therefore, costs of this low-efficiency drug packaging, where medication packages are started but not completed, in high-cost medications are substantial and should be properly addressed. Any improvement in the packaging by the manufacturer, and favoring the choice of drugs supplied through efficient packages (when efficacy, toxicity, and convenience are similar), should minimize the treatment expenditures paid by national health budgets. en
dc.format application/pdf
dc.format.extent 4 p.
dc.language.iso eng
dc.publisher Dove Medical Press ca_ES
dc.rights Aquest document està subjecte a aquesta llicència Creative Commons ca_ES
dc.rights.uri http://creativecommons.org/licenses/by/3.0/es/ ca_ES
dc.subject.other Sida -- Tractament ca_ES
dc.title Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging en
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.2147/DDDT.S87075
dc.rights.accesRights info:eu-repo/semantics/openAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a SCOPUS ca_ES
dc.indexacio Indexat a WOS/JCR

Files in this item

Show simple item record

Aquest document està subjecte a aquesta llicència Creative Commons Except where otherwise noted, this item's license is described as Aquest document està subjecte a aquesta llicència Creative Commons

Search RIUVic


Advanced Search

Browse

Statistics